What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Supplier-branded aesthetic / lipolytic solution
Overview
Lemon Bottle is a Korean-origin supplier-branded aesthetic injectable solution marketed in the medical-aesthetic industry as a lipolytic / fat-dissolving product. The formulation is typically a multi-component aqueous solution containing combinations of riboflavin (the yellow color that gives the brand its name), bromelain enzyme, lecithin, and other lipotropic components, though the exact composition is proprietary to the upstream manufacturer and varies between commercial versions. Lemon Bottle and similar lipolytic injectables (Aqualyx, Kybella for the deoxycholic-acid-based formulations) are used by med-spa providers in localized fat-reduction procedures, but the regulatory status varies dramatically by jurisdiction, approved in some Asian markets, off-label in others, and prohibited in others. PeptideXpo distributes Lemon Bottle only to qualified buyers with appropriate licensing for aesthetic-injectable use in their destination jurisdiction. The component composition on every shipment is documented against the upstream formulation sheet, and buyers should verify the components are permitted in their target market before order placement, Korean-origin aesthetic injectables in particular have varying regulatory acceptance across EU, US, and Commonwealth markets.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: medical aesthetic clinics and med spas and regional distributors and re-sellers.
Specifications
Documentation available on request
Regulatory note
Korean-origin aesthetic injectable; regulatory status varies dramatically by jurisdiction. Sold only to qualified buyers with appropriate licensing for aesthetic-injectable use. Order requires compliance review against the destination market's current regulatory posture for similar Korean-origin lipolytic injectables.
Frequently asked questions
Lemon Bottle and similar Korean-origin lipolytic injectables are typically multi-component aqueous formulations containing riboflavin (B-2), bromelain enzyme, lecithin, and other lipotropic components. They are mechanistically distinct from deoxycholic-acid-based injectables (Kybella in the US, Belkyra in EU) which use a single active that physically disrupts adipocyte membranes. The Korean-origin multi-component formulations are typically marketed with milder claimed action and are not pharmacologically equivalent to deoxycholic-acid products despite similar marketed indications. Buyers should match the product to their specific clinical use case and verify regulatory status in the target jurisdiction.
Lemon Bottle and similar Korean-origin aesthetic injectables have varied regulatory acceptance across major markets: approved or tolerated in several Asian markets where they originate; off-label or grey-market in the UK and parts of EU; prohibited or strongly restricted in the US (FDA does not recognize them as approved injectables). The composition itself uses ingredients that are individually established but the finished-product approval status is jurisdiction-specific. PeptideXpo distributes only to qualified buyers who have verified the product's regulatory status in their destination market and have the appropriate aesthetic-injectable licensing.
Med-spa providers using Korean-origin lipolytic injectables typically follow protocols developed in the Korean and Southeast Asian aesthetic-medicine literature: small-volume (typically 1-3 mL per injection site) subcutaneous administration into localized fat deposits, with sessions repeated every 2-4 weeks for 3-6 total treatments. The clinical observation is that these multi-component aqueous formulations produce gradual, modest local fat reduction rather than the more aggressive effect of deoxycholic-acid-based injectables. Treatment areas typically include submental fat ('double chin'), small subcutaneous deposits on the trunk, and similar localized sites where surgical liposuction would be disproportionate. Buyers should reference the destination-market's aesthetic-medicine regulatory framework before clinical use.
